Comparison of the therapeutic effectiveness of the drug Mucosat based on glycosaminoglycans in oral and parenteral dosage forms in the treatment of osteoarthritis

封面
  • 作者: Peshekhonova L.1,2, Peshekhonov D.3,4, Pyatibrat A.5, Vengerovich N.6,7
  • 隶属关系:
    1. N.N. Burdenko Voronezh State Medical University of the Ministry of Health of the Russian Federation, Voronezh, Russia
    2. Non-state Health Care Facility “Road Clinical Hospital at the station Voronezh-1 of JSC Russian Railways”
    3. N.N. Burdenko Voronezh State Medical University of the Ministry of Health of the Russian Federation
    4. Road Clinical Hospital at the station Voronezh-1 of JSC Russian Railways
    5. Saint-Petersburg State Pediatric Medical University of the Ministry of Health of the Russian Federation
    6. State Research Testing Institute of Military Medicine of the Ministry of Defense of the Russian Federation
    7. Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Health of the Russian Federation
  • 期: 卷 3, 编号 1 (2021)
  • 页面: 66-75
  • 栏目: Biomedical Sciences
  • URL: https://journals.rcsi.science/PharmForm/article/view/60598
  • DOI: https://doi.org/10.17816/phf60598
  • ID: 60598

如何引用文章

全文:

详细

The study aims to compare the methods of Mucosat drug use and administration for achieving the desired therapeutic effect in the treatment of osteoarthritis.

Despite extensive evidence base, improving complex therapy schemes for the use of successive and complementary dosage forms with the appropriate drug administration and use in order to achieve the desired therapeutic effect is still a valid aim.

In the course of the study, 50 knee osteoarthritis patients were examined and treated during the period from November, 2019 to April, 2020.

A clinical trial was carried out to assess Mucosat oral and parental administration effectiveness in the patients comparing their physical activity, functional ability and quality of life. The number of undesired side effects identified the degree of therapeutic tolerance against the comorbid diseases identified. A comparison of the therapeutic efficacy and tolerability of Musocat intramuscular and capsule administration, patient compliance, the need to take non-steroidal anti-inflammatory drugs (NSAIDs) was drawn.

Statistica 12 and Excel 2016 were used to carry out the statistical analysis of the data obtained. The study was generally marked by diagnostic accuracy with the use of modern methods, group homogeneity, prospective observational design.

By the time of pharmacotherapy completion, physical activity has become optimal in the study groups. However, parental therapy had significantly higher effectiveness than the oral one on all the subscales. As a result, articular syndrome severity has been reduced and the functional state of the joints expanded.

The study has shown that Mucosat demonstrates high efficacy both in injectable solution and capsule dosage forms as a basic chondroprotective drug. Mucosat pharmacotherapy course has contributed to permanent discontinuation of NSAIDs before completion of the therapy. The superiority of Mucosat parenteral administration over the oral one has been proven.

作者简介

Lyudmila Peshekhonova

N.N. Burdenko Voronezh State Medical University of the Ministry of Health of the Russian Federation, Voronezh, Russia; Non-state Health Care Facility “Road Clinical Hospital at the station Voronezh-1 of JSC Russian Railways”

Email: dmmad@yandex.ru

Doctor of Medicine (MD), Professor of the Department of Industrial Medicine, N.N. Burdenko Voronezh State Medical University of the Ministry of Health of the Russian Federation; Head of the Rheumatology Department, Road Clinical Hospital at the station Voronezh-1 of JSC Russian Railways

俄罗斯联邦, Voronezh; Voronezh

Dmitry Peshekhonov

N.N. Burdenko Voronezh State Medical University of the Ministry of Health of the Russian Federation; Road Clinical Hospital at the station Voronezh-1 of JSC Russian Railways

Email: dmmad@yandex.ru

Doctor of Medicine (MD), rheumatologist of the rheumatology department, Road Clinical Hospital at the station Voronezh-1 of JSC Russian Railways; N.N. Burdenko Voronezh State Medical University of the Ministry of Health of the Russian Federation

俄罗斯联邦, Voronezh; Voronezh

Alexander Pyatibrat

Saint-Petersburg State Pediatric Medical University of the Ministry of Health of the Russian Federation

Email: a5brat@yandex.ru

Doctor of Medicine (MD), Professor of the Department of Mobilization Training of Public Health and Disaster Medicine, Saint-Petersburg State Pediatric Medical University of the Ministry of Health of the Russian Federation

俄罗斯联邦, Saint Petersburg

Nikolai Vengerovich

State Research Testing Institute of Military Medicine of the Ministry of Defense of the Russian Federation; Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Health of the Russian Federation

编辑信件的主要联系方式.
Email: nikolai.vengerovich@pharminnotech.com
ORCID iD: 0000-0003-3219-341X
SPIN 代码: 6690-9649
Scopus 作者 ID: 55639823300
Researcher ID: U-3467-2019

Doctor of Medicine (MD), Deputy Head of the Department of the Research and Testing Center (Medical and Biological Protection), State Scientific Research Testing Institute of Military Medicine of the Ministry of Defense of the Russian Federation; Professor at the Industrial Ecology Department, Saint Petersburg State Chemical and Pharmaceutical University

俄罗斯联邦, Saint Petersburg; Saint Petersburg

参考

  1. Мазуров, В.И. Хондропротекторы в клинике остеоартроза: лечение и прогноз / В.И. Мазуров, М.С. Шестак, В.В. Рипачев // Фарматека. – 2013. – № 19 (272). – С. 45–50.
  2. Пешехонова, Л.К. Современные тенденции патогенетической терапии остеоартроза / Л.К. Пешехонова, Д.В. Пешехонов // Российский медицинский журнал. – 2012. – Т. 20. – № 30. – С. 1500–1503.
  3. Шостак, Н.А. Остеоартроз – новые возможности симптом-модифицирующей терапии замедленного действия / Н.А. Шостак, Н.Г. Правдюк, А.А. Клименко [и др.] // Клиницист. – 2013. – № 3–4. – С. 93–97.
  4. Hochberg MC. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthr Cartil. 2010; Suppl 1: S28–S31. doi: 10.1016/j.joca.2010.02.016.
  5. Hunziker EB. Articular cartilage repair: basic science and clinical progress. A review of the current status and prospects. Osteoarthritis Cartilage. 2002; 10 (6): 432–63. doi: 10.1053/joca.2002.0801.
  6. Pereira D, Peleteiro B, Araújo J, et al. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage. 2011; 19 (11): 1270–85. doi: 10.1016/j.joca.2011.08.009.
  7. Кузовкина, Т.Н. Проведение ступенчатой терапии хондропротекторами больным первичным остеоартрозом / Т.Н. Кузовкина, Л.К. Пешехонова, Д.В. Пешехонов // Материалы 17-го Российского национального конгресса «Человек и лекарство». – Москва, 2010. – С. 156.
  8. Венгерович, Н.Г. Подходы к оценке количественного состава лекарственных средств на основе пептидов природного происхождения, содержащих гликозаминогликан-пептидный комплекс / Н.Г. Венгерович, Н.В. Ефимов, Н.И. Рогожина, В.И. Степчинков // Формулы Фармации. – 2020. – Т. 2. – №. 1. – С. 8-15. doi: 10.17816/phf20390/2713-153x-2020-1-2-08-15.
  9. Николаева, Т.И. Разработка комплекса низкомолекулярных пептидов коллагена с гликозаминогликановыми компонентами / Т.И. Николаева, К.С. Лауринавичюс, В.В. Капцов [и др.] // Бюллетень экспериментальной биологии и медицины. – 2018. – Т. 165. – № 5. – С. 571–576. doi: 10.1007/s10517-018-4229-0.
  10. Camarero-Espinosa S, Cooper-White J.J. Combinatorial presentation of cartilage-inspired peptides on nanopatterned surfaces enables directed differentiation of human mesenchymal stem cells towards distinct articular chondrogenic phenotypes. Biomaterials. 2019; 210: 105–15. doi: 10.1016/j.biomaterials.2019.04.003.
  11. Пешехонова, Л.К. Актуальные вопросы терапии остеоартроза в реальной клинической практике / Л.К. Пешехонова, Д.В. Пешехонов, П.А. Красюков // Медицинский совет. – 2017. – № 1S. – С. 97–102.
  12. Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. CPMP/EWP/784/97. Rev. 1. London: European Medicines Agency, 2010.
  13. Аникин, С.Г. Хондроитина сульфат: механизмы действия, эффективность, безопасность при терапии остеоартроза / С.Г. Аникин, Л.И. Алексеева // Современная ревматология. – Т. 6. – № 3. – 2012. – С. 78–82.
  14. Зоткин, Е.Г. Возможности клинического применения хондроитин сульфата для парентерального введения у пациентов с остеоартрозом в гериатрической практике / Е.Г. Зоткин, Т.В. Харитонова, С.Ю. Шкиреева // Успехи геронтологии. – 2014. – Т. 27. – № 2. – С. 366–375.
  15. Капустина, Н.В. Хондропротекторная терапия (инъекционная форма хондроитина сульфата) посттравматического остеоартроза коленных суставов / Н.В. Капустина, Т.Д. Кобракова // Лечащий врач. – 2013. – № 7. – С. 112.
  16. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001; 357 (9252): 251–6. doi: 10.1016/S0140-6736(00)03610-2.
  17. Reginster JY, Neuprez A, Lecart M, et al. Role of glucosamine in the treatment for osteoarthritis. Rheumatol Int. 2012; 32 (10): 2959–67. doi: 10.1007/s00296-012-2416-2.
  18. Martel-Pelletier J, Lajeunesse D, Pelletier J-P. Etiopathogenesis of osteoarthritis. Arthritis and Allied Conditions: A Textbook of Rheumatology. 15th Edition. In: Koopman WJ, Moreland LW, editors. Baltimore, USA: Lippincott, Williams & Wilkins, 2005; 2199–2226.
  19. Лапшина, С.А. Исследование эффективности, безопасности и переносимости сочетанного применения препаратов глюкозамина сульфата («Артракам») и хондроитина сульфата («Артрадол») у пациентов с остеоартрозом коленных суставов / С.А. Лапшина, М.А. Афанасьева, Е.В. Сухорукова // Вестник современной клинической медицины. – 2016. – Т. 9. – № 1. – С. 45–51.
  20. Lee YH, Woo JH, Choi SJ, et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a metaanalysis. Rheumatol. Int. 2010; 30: 357–363. doi: 10.1007/s00296-009-0969-5.
  21. Волошин, В.П. Исследование эффективности действия препарата Хондрогард (хондроитина сульфат) у пациентов с остеоартрозом / В.П. Волошин, А.В. Еремин, С.А. Санкаранараянан [и др.] // Трудный пациент. – 2015. – Т. 13. – № 2. – С. 29–33.
  22. Kahan A, Uebelhart D, Vathaire F, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis and rheumatism. 2009; 60 (2): 524–33. doi: 10.1002/art.24255.
  23. Veronese N, Demurtas J, Smith L, et al. Glucosamine sulphate: an umbrella review of health outcomes. Ther Adv Musculoskelet Dis. 2020; 12: 1759720X20975927. doi: 10.1177/1759720X20975927.
  24. Roman-Blas JA, Castañeda S, Sánchez-Pernaute O, et al. Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Six‐Month Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial. Arthritis Rheumatol. 2017; 69 (1): 77–85. doi: 10.1002/art.39819.
  25. WOMAC Osteoarthritis Index. Physiopedia [Internet]. Available from: https://www.physio-pedia.com/WOMAC_Osteoarthritis_Index.
  26. Golubev G, Baranenko A. Validation and reliability of Russian version of KOOS. KOOS [Internet]. Available from: http://www.koos.nu/russian.pdf.

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Trends in pain intensity on the visual analogue scale (VAS) in the groups

下载 (106KB)
索引源数据
3. Fig. 2. Trends in activities of daily living applying the Lequesne index

下载 (45KB)
索引源数据
4. Fig. 3. Trends in stiffness on the WOMAC

下载 (126KB)
索引源数据
5. Fig. 4. Functional ability and quality of life total score using the EQ-5D

下载 (126KB)
索引源数据
6. Fig. 5. Comparison of the KOOS questionnaire total score

下载 (145KB)
索引源数据

版权所有 © Peshekhonova L.K., Peshekhonov D.V., Pyatibrat A.O., Vengerovich N., 2021

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。
 


##common.cookie##